Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 9/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | TP53 | P04637 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264348 | 0.85 | PIP4K2A (0.76) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6266583 | 0.85 | LMNA (0.73) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6264125 | 0.83 | MAPT (0.74) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6271125 | 0.82 | MAPT (0.82) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6265421 | 0.81 | MAPT (1.00) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6264522 | 0.78 | LMNA (0.65) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6268886 | 0.77 | LMNA (0.73) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6264511 | 0.77 | MAPT (0.78) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6270299 | 0.77 | MAPT (0.78) | PIP4K2AMAPTTP53LMNAKDM4E | |
| SCHEMBL6267297 | 0.77 | MAPT (0.81) | PIP4K2AMAPTTP53LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005047288-A1 | PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |